Thermo Fisher Scientific (TMO) stock price, revenue, and financials

Thermo Fisher Scientific market cap is $206.1 b, and annual revenue was $32.22 b in FY 2020

$206.1 B

TMO Mkt cap, 22-Jul-2021

$32.2 B

Thermo Fisher Scientific Revenue FY, 2020
Thermo Fisher Scientific Revenue growth (FY, 2019 - FY, 2020), %26%
Thermo Fisher Scientific Gross profit (FY, 2020)16.5 B
Thermo Fisher Scientific Gross profit margin (FY, 2020), %51.2%
Thermo Fisher Scientific Net income (FY, 2020)6.4 B
Thermo Fisher Scientific EBIT (FY, 2020)7.8 B
Thermo Fisher Scientific Cash, 31-Dec-202010.3 B
Thermo Fisher Scientific EV217.6 B
Get notified regarding key financial metrics and revenue changes at Thermo Fisher ScientificLearn more
Banner background

Thermo Fisher Scientific Revenue

Thermo Fisher Scientific revenue was $32.22 b in FY, 2020 which is a 26.1% year over year increase from the previous period.

Embed Graph

Thermo Fisher Scientific Revenue Breakdown

Embed Graph

Thermo Fisher Scientific revenue breakdown by business segment: 35.1% from Laboratory Products and Services, 15.3% from Specialty Diagnostics, 14.7% from Analytical Instruments and 34.9% from Life Sciences Solutions

Thermo Fisher Scientific revenue breakdown by geographic segment: 8.7% from China, 51.0% from United States and 40.3% from Other

Thermo Fisher Scientific Income Statement

Annual

USDFY, 2018FY, 2019FY, 2020

Revenue

24.4b25.5b32.2b

Revenue growth, %

16%5%26%

Cost of goods sold

13.5b14.2b15.7b

Gross profit

10.9b11.3b16.5b

Gross profit Margin, %

45%44%51%

R&D expense

967.0m1.0b1.2b

General and administrative expense

6.1b6.1b6.9b

Operating expense total

10.9b7.1b8.1b

EBIT

3.8b4.6b7.8b

EBIT margin, %

16%18%24%

Interest expense

676.0m553.0m

Interest income

224.0m65.0m

Pre tax profit

3.3b4.1b7.2b

Income tax expense

324.0m374.0m850.0m

Net Income

2.9b3.7b6.4b

EPS

7.29.216.0

Thermo Fisher Scientific Balance Sheet

Annual

USDFY, 2018FY, 2019FY, 2020

Cash

2.1b2.4b10.3b

Accounts Receivable

4.1b4.3b5.7b

Inventories

3.0b3.4b4.0b

Current Assets

10.6b11.9b22.0b

PP&E

4.2b4.7b5.9b

Goodwill

25.3b25.7b26.0b

Total Assets

56.2b58.4b69.1b

Accounts Payable

1.6b1.9b2.2b

Short-term debt

1.3b676.0m2.6b

Current Liabilities

6.1b6.2b10.3b

Long-term debt

17.7b17.1b19.1b

Non-Current Liabilities

22.5b22.5b

Total Debt

19.0b17.8b21.7b

Total Liabilities

28.6b28.7b

Common Stock

432.0m434.0m437.0m

Additional Paid-in Capital

14.6b15.1b15.6b

Retained Earnings

18.7b22.1b28.1b

Total Equity

27.6b29.7b34.5b

Debt to Equity Ratio

0.7 x0.6 x0.6 x

Debt to Assets Ratio

0.3 x0.3 x0.3 x

Financial Leverage

2 x2 x2 x

Thermo Fisher Scientific Cash Flow

Annual

USDFY, 2018FY, 2019FY, 2020

Net Income

2.9b3.7b6.4b

Depreciation and Amortization

2.3b2.3b2.3b

Accounts Receivable

(366.0m)(225.0m)(1.3b)

Inventories

(324.0m)(458.0m)(508.0m)

Accounts Payable

201.0m266.0m59.0m

Cash From Operating Activities

4.5b5.0b8.3b

Purchases of PP&E

(758.0m)(926.0m)(1.5b)

Cash From Investing Activities

(1.3b)(1.5b)(1.5b)

Long-term Borrowings

(2.1b)(6.4b)(1.1b)

Dividends Paid

(266.0m)(297.0m)(337.0m)

Cash From Financing Activities

(2.2b)(3.1b)959.0m

Net Change in Cash

756.0m305.0m7.9b

Thermo Fisher Scientific Ratios

USDQ1, 2018

Debt/Equity

0.8 x

Debt/Assets

0.4 x

Financial Leverage

2.2 x

Thermo Fisher Scientific Operating Metrics

Thermo Fisher Scientific's Customers was reported to be 400 k in FY, 2020. Thermo Fisher Scientific's Backlog was reported to be $7.8b in FY, 2019.
FY, 2017FY, 2018FY, 2019FY, 2020

Backlog

$4.46 b$5.09 b$7.77 b

Backlog (Analytical Instruments)

$2.05 b$2.24 b$2.2 b

Backlog (Laboratory Products and Services)

$1.68 b$2.06 b$4.58 b

Backlog (Life Sciences Solutions)

$594 m$647 m$893 m

Backlog (Specialty Diagnostics)

$158 m$187 m$172 m

Customers

400 k400 k400 k400 k

Remaining Performance Obligations

$12.81 b

Thermo Fisher Scientific Sustainability Metrics

 FY, 2019

Сorporate Сontributions

1.8 m

Waste Diverted from Landfills

4.3 k tons

Volunteer Hours

115 k

Thermo Fisher Scientific Human Capital

Thermo Fisher Scientific's employees are reported to be approximately 41% female and 59% male.

Gender

FY, 2019
Male58.8%
Female40.4%
Other0.8%